Novian Health Earns New Product Innovation Award for Novilase Breast Therapy
Retrieved on:
Tuesday, December 6, 2022
Laser, Perception, Annals of Surgical Oncology, Coagulative necrosis, Scar, Breast, Laser medicine, Patient, Frost, Sengupta, Breast cancer, Fatigue, Neoplasm, FDA, Health, Woman, Surgical oncology, Quality of life, Trauma, Cancer, Record, Multimedia, Temperature, Malignancy, Medical imaging, Pharmaceutical industry
CHICAGO, Dec. 6, 2022 /PRNewswire/ -- Novian Health has received Frost & Sullivan's 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase® Breast Therapy system. Novilase, a minimally invasive procedure that uses laser ablation to destroy tumors as an alternative to surgery, has the potential to make "the treatment of breast cancer much simpler and more effective, with significantly lower side effects," according to Frost & Sullivan's evaluation.
Key Points:
- CHICAGO, Dec. 6, 2022 /PRNewswire/ -- Novian Health has received Frost & Sullivan's 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase Breast Therapy system.
- Novilase is a thermal ablation device that uses laser heat to destroy tumor cells without lumpectomy surgery.
- "Laser therapy can help patients avoid the trauma and risks of breast cancer surgery," said Henry Appelbaum, president and CEO of Novian Health.
- "The Novian Health team is proud to receive this award as we begin to offer the benefits of this game-changing technology to breast cancer patients in Europe."